AbbVie buys Third Rock’s Celsius for $250M to expand IBD pipeline

As Ab­b­Vie con­tin­ues to tout its next gen­er­a­tion of im­munol­o­gy drugs be­hind Hu­mi­ra, it’s buy­ing an ear­ly-stage start­up to boost its longer-term prospects in in­flam­ma­to­ry …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.